Cargando…

The Potential Prognostic Value of a Novel Hematologic Marker Fibrinogen-to-Lymphocyte Ratio in Head and Neck Adenoid-Cystic Carcinoma

Many patients with adenoid-cystic carcinoma (ACC) experience an indolent course of disease over many years but face late recurrence, and long-term survivors are rare. Due to its infrequent occurrence, it is hard to predict outcome in these patients. The fibrinogen-to-lymphocyte ratio (FLR) was recen...

Descripción completa

Detalles Bibliográficos
Autores principales: Brkic, Faris F., Stoiber, Stefan, Friedl, Marlene, Maier, Tobias, Heiduschka, Gregor, Kadletz-Wanke, Lorenz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8620294/
https://www.ncbi.nlm.nih.gov/pubmed/34834580
http://dx.doi.org/10.3390/jpm11111228
_version_ 1784605185880883200
author Brkic, Faris F.
Stoiber, Stefan
Friedl, Marlene
Maier, Tobias
Heiduschka, Gregor
Kadletz-Wanke, Lorenz
author_facet Brkic, Faris F.
Stoiber, Stefan
Friedl, Marlene
Maier, Tobias
Heiduschka, Gregor
Kadletz-Wanke, Lorenz
author_sort Brkic, Faris F.
collection PubMed
description Many patients with adenoid-cystic carcinoma (ACC) experience an indolent course of disease over many years but face late recurrence, and long-term survivors are rare. Due to its infrequent occurrence, it is hard to predict outcome in these patients. The fibrinogen-to-lymphocyte ratio (FLR) was recently proposed as an outcome prognosticator in different cancer entities. We aimed to investigate its prognostic relevance in patients with head and neck ACC. This retrospective analysis was performed including all patients treated for ACC between 1998 and 2020. The FLR ratio was calculated based on pretreatment values (0–7 days). The study cohort was dichotomized based on optimized threshold value and compared for differences in outcome (overall survival (OS) and disease-free survival (DFS)). In the cohort of 39 included patients, the OS was significantly longer in the low (n = 28) compared to the high pretreatment FLR group (n = 11) (median OS 150.5 months, 95% confidence intervals (CI) 85.3–215.7 months vs. 29.4 months, 95% CI not reached; p = 0.0093). Similarly, the DFS was significantly longer in the low FLR group (median DFS 74.5 months, 95% CI 30.6–118.4 months vs. 11.0 months, 95% CI 5.1–16.9 months; p = 0.019). The FLR is an easily obtainable and simple marker and may be a valuable outcome prognosticator in patients with ACC. Further studies are needed for validation of our results.
format Online
Article
Text
id pubmed-8620294
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86202942021-11-27 The Potential Prognostic Value of a Novel Hematologic Marker Fibrinogen-to-Lymphocyte Ratio in Head and Neck Adenoid-Cystic Carcinoma Brkic, Faris F. Stoiber, Stefan Friedl, Marlene Maier, Tobias Heiduschka, Gregor Kadletz-Wanke, Lorenz J Pers Med Article Many patients with adenoid-cystic carcinoma (ACC) experience an indolent course of disease over many years but face late recurrence, and long-term survivors are rare. Due to its infrequent occurrence, it is hard to predict outcome in these patients. The fibrinogen-to-lymphocyte ratio (FLR) was recently proposed as an outcome prognosticator in different cancer entities. We aimed to investigate its prognostic relevance in patients with head and neck ACC. This retrospective analysis was performed including all patients treated for ACC between 1998 and 2020. The FLR ratio was calculated based on pretreatment values (0–7 days). The study cohort was dichotomized based on optimized threshold value and compared for differences in outcome (overall survival (OS) and disease-free survival (DFS)). In the cohort of 39 included patients, the OS was significantly longer in the low (n = 28) compared to the high pretreatment FLR group (n = 11) (median OS 150.5 months, 95% confidence intervals (CI) 85.3–215.7 months vs. 29.4 months, 95% CI not reached; p = 0.0093). Similarly, the DFS was significantly longer in the low FLR group (median DFS 74.5 months, 95% CI 30.6–118.4 months vs. 11.0 months, 95% CI 5.1–16.9 months; p = 0.019). The FLR is an easily obtainable and simple marker and may be a valuable outcome prognosticator in patients with ACC. Further studies are needed for validation of our results. MDPI 2021-11-19 /pmc/articles/PMC8620294/ /pubmed/34834580 http://dx.doi.org/10.3390/jpm11111228 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Brkic, Faris F.
Stoiber, Stefan
Friedl, Marlene
Maier, Tobias
Heiduschka, Gregor
Kadletz-Wanke, Lorenz
The Potential Prognostic Value of a Novel Hematologic Marker Fibrinogen-to-Lymphocyte Ratio in Head and Neck Adenoid-Cystic Carcinoma
title The Potential Prognostic Value of a Novel Hematologic Marker Fibrinogen-to-Lymphocyte Ratio in Head and Neck Adenoid-Cystic Carcinoma
title_full The Potential Prognostic Value of a Novel Hematologic Marker Fibrinogen-to-Lymphocyte Ratio in Head and Neck Adenoid-Cystic Carcinoma
title_fullStr The Potential Prognostic Value of a Novel Hematologic Marker Fibrinogen-to-Lymphocyte Ratio in Head and Neck Adenoid-Cystic Carcinoma
title_full_unstemmed The Potential Prognostic Value of a Novel Hematologic Marker Fibrinogen-to-Lymphocyte Ratio in Head and Neck Adenoid-Cystic Carcinoma
title_short The Potential Prognostic Value of a Novel Hematologic Marker Fibrinogen-to-Lymphocyte Ratio in Head and Neck Adenoid-Cystic Carcinoma
title_sort potential prognostic value of a novel hematologic marker fibrinogen-to-lymphocyte ratio in head and neck adenoid-cystic carcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8620294/
https://www.ncbi.nlm.nih.gov/pubmed/34834580
http://dx.doi.org/10.3390/jpm11111228
work_keys_str_mv AT brkicfarisf thepotentialprognosticvalueofanovelhematologicmarkerfibrinogentolymphocyteratioinheadandneckadenoidcysticcarcinoma
AT stoiberstefan thepotentialprognosticvalueofanovelhematologicmarkerfibrinogentolymphocyteratioinheadandneckadenoidcysticcarcinoma
AT friedlmarlene thepotentialprognosticvalueofanovelhematologicmarkerfibrinogentolymphocyteratioinheadandneckadenoidcysticcarcinoma
AT maiertobias thepotentialprognosticvalueofanovelhematologicmarkerfibrinogentolymphocyteratioinheadandneckadenoidcysticcarcinoma
AT heiduschkagregor thepotentialprognosticvalueofanovelhematologicmarkerfibrinogentolymphocyteratioinheadandneckadenoidcysticcarcinoma
AT kadletzwankelorenz thepotentialprognosticvalueofanovelhematologicmarkerfibrinogentolymphocyteratioinheadandneckadenoidcysticcarcinoma
AT brkicfarisf potentialprognosticvalueofanovelhematologicmarkerfibrinogentolymphocyteratioinheadandneckadenoidcysticcarcinoma
AT stoiberstefan potentialprognosticvalueofanovelhematologicmarkerfibrinogentolymphocyteratioinheadandneckadenoidcysticcarcinoma
AT friedlmarlene potentialprognosticvalueofanovelhematologicmarkerfibrinogentolymphocyteratioinheadandneckadenoidcysticcarcinoma
AT maiertobias potentialprognosticvalueofanovelhematologicmarkerfibrinogentolymphocyteratioinheadandneckadenoidcysticcarcinoma
AT heiduschkagregor potentialprognosticvalueofanovelhematologicmarkerfibrinogentolymphocyteratioinheadandneckadenoidcysticcarcinoma
AT kadletzwankelorenz potentialprognosticvalueofanovelhematologicmarkerfibrinogentolymphocyteratioinheadandneckadenoidcysticcarcinoma